Neuropsych testing denied? We cite NAN, AACN, INS, and the policy language insurers respect.

Why neuropsych testing denials are particularly frustrating

A denied neuropsychological evaluation sits in an awkward gap. It is not a drug, not a surgery, not a piece of imaging — it is hours of standardized testing administered and interpreted by a doctoral-level clinician, and the bills look like (and often are) thousands of dollars. Insurers see CPT 96132/96133 with multiple hours of 96136/96137 piling up and reflexively classify it as either "duplicative" of a five-minute screen or as something a psychiatrist could do in a clinical interview.

That framing is wrong, and the appeal letter has to say so explicitly. The good news: there is a single controlling document for medical necessity in this space — the NAN 2019 Medical Necessity Position Paper (Block et al., Archives of Clinical Neuropsychology) — and almost every insurer's coverage policy is downstream of it. When the appeal letter cites NAN 2019 by name, quotes the insurer's own coverage criteria, and shows that brief screening was tried and was inadequate to answer the referral question, most denials reverse.

This guide walks through the most common denial categories for neuropsych testing, exactly which evidence to cite, and how to structure the appeal letter so it survives medical-director review.

The denial categories you will actually see

Across thousands of neuropsych testing denials, six reasons account for nearly all rejections:

1. "Duplicative of prior screening" — typically applied when a MoCA, MMSE, or ASRS-v1.1 has been documented in the chart. Insurers will argue the question has already been answered.

2. "Self-pay required for ADHD" — Aetna, Cigna, and several BCBS plans have at various times tried to push adult ADHD evaluations out of medical benefits. This is wrong and rarely survives appeal.

3. "Hours exceed plan limit" — most plans soft-cap at 6 to 8 hours; complex batteries (TBI, dementia differential, presurgical) often need 8 to 12.

4. "Not medically necessary" — usually means the referral question was vague.

5. "Screening (MoCA / MMSE) is sufficient for dementia workup" — common with Cigna and Humana Medicare Advantage.

6. "ASD evaluation is experimental" — almost always wrong; ADOS-2 and ADI-R are referenced in DSM-5-TR.

Each one has a specific counter, and they are not subtle.

The NAN 2019 Medical Necessity Position Paper: the document insurers cite without realizing it

If you read only one citation for a neuropsych appeal, it is the NAN 2019 Medical Necessity Position Paper. Block, Johnson-Greene, and colleagues laid out three criteria that have since been adopted, in spirit if not by name, by every major commercial insurer's coverage policy:

1. The referral question concerns brain-behavior relationships that cannot be answered by clinical interview or brief screening alone.

2. Test results are expected to change management — diagnosis, medication selection, school accommodations, surgical clearance, capacity determination, return-to-work or return-to-play decisions.

3. The evaluation is administered and interpreted by a qualified neuropsychologist (board-certified ABPP-CN / ABCN status materially strengthens this).

Quoting these three criteria back at the insurer, then walking through how each is met, is the spine of a successful appeal. Aetna CPB 0158, UHC's psychological/neuropsychological testing policy, Cigna's coverage policy, and Anthem CG-BEH-09 all mirror this structure.

"Duplicative of prior screening": the most common denial

The MoCA was designed as a screening tool. So was the MMSE, and the ASRS-v1.1, and the SLUMS. These take 5 to 15 minutes, are not normed for differential diagnosis, and were never meant to substitute for a comprehensive battery. The successful counter-argument:

• Submit the screening result with the actual score (e.g., MoCA 22/30 with impaired delayed recall and clock).
• Explain why the screening cannot resolve the referral question. A 22/30 MoCA tells you something is wrong; it does not differentiate MCI from major depression with cognitive features, from ADHD with comorbid anxiety, from a focal frontal-subcortical syndrome, or from a primary progressive aphasia.
• Cite Petersen AAN MCI 2018 (Neurology) — comprehensive neuropsychological testing has higher sensitivity and specificity than screening tools for the MCI vs dementia differential.
• Cite NAN 2019 — screening is necessary but not sufficient when the referral question requires a quantitative cognitive profile across domains.
• List the specific domains the comprehensive battery will cover that the screen does not: memory (with separate verbal and visual modalities), executive functioning, language, visuospatial, attention, processing speed, and embedded performance / symptom validity testing.

Once the screening is reframed as the trigger for the comprehensive evaluation rather than a substitute for it, the "duplicative" framing collapses.

"Self-pay required for ADHD": the insurer is wrong

Aetna, several BCBS plans, and Cigna at times have sent denials suggesting that adult ADHD evaluation is "not a medical service" or "should be paid out of pocket." This is contrary to DSM-5-TR, contrary to the AAP 2019 Clinical Practice Guideline (Wolraich, Pediatrics), and contrary to the insurers' own coverage policies. ADHD is a medical diagnosis. Treatment with stimulants and atomoxetine carries cardiovascular and psychiatric monitoring requirements. Comorbidities (anxiety, depression, learning disability, mild TBI sequelae, sleep disorders) shape both diagnosis and management.

The successful adult ADHD appeal:

• Cite Aetna CPB 0158 explicitly — ADHD differential is a covered indication when comorbidities or atypical presentation are present.
• Submit ASRS-v1.1 score and quote the WHO scoring criteria.
• Submit Wender Utah Rating Scale for retrospective childhood symptoms (DSM-5-TR requires onset before age 12).
• Submit CAARS T-scores by subscale (inattention, hyperactivity-impulsivity, problems with self-concept, DSM-IV symptom subscales).
• Submit DIVA-5 (Diagnostic Interview for ADHD in Adults, 5th edition) structured interview findings.
• Document functional impairment across two or more domains (work, school, relationships, finances, driving).
• Cite Faraone et al. 2024 World Federation of ADHD Consensus Statement and Kessler et al. prevalence data establishing adult ADHD as a discrete medical diagnosis.

Insurers reviewing this packet rarely sustain the "self-pay" denial.

"Hours exceed plan limit": itemize by CPT code

Most plans soft-cap psychological testing at 6 to 8 hours. Complex batteries — moderate-severe TBI, dementia differential, presurgical evaluation, complex ASD — routinely need 8 to 12 hours. The 2019 CPT code overhaul matters here: 96132 covers the first hour of professional evaluation (interview, integration, interpretation, report writing, feedback), 96133 each additional hour. 96136 is the first 30 minutes of test administration and scoring by the professional, 96137 each additional 30 minutes. 96138 / 96139 are technician administration. 96130 / 96131 are psychological testing (non-neuropsych) hours. 96116 and 96121 are the neurobehavioral status exam family.

The successful "hours exceeded" appeal:

• Itemize hours by CPT code: 1 hour clinical interview + collateral (96132), 4-6 hours test administration and scoring (96136/96137), 2-3 hours interpretation and report (96133), 1 hour feedback (96133).
• Cite AACN Practice Guidelines (2007) — comprehensive batteries with embedded validity testing typically require 8 to 12 hours.
• Cite the Heilbronner consensus statement on validity testing (Clinical Neuropsychologist 2009) — performance and symptom validity tests should be embedded throughout the battery, which adds time but is required by professional standards.
• For TBI, cite the AAN Mild TBI guideline (Carney 2019) and the CDC Pediatric mTBI guideline (Lumba-Brown JAMA Pediatr 2018) — comprehensive cognitive assessment is recommended for symptomatic mTBI / persistent post-concussion symptoms.
• For dementia, cite the AAN MCI guideline (Petersen Neurology 2018).
• For presurgical, cite the ILAE presurgical framework, the MDS Task Force / CAPSIT-PD criteria for DBS, or the ASMBS guidelines for bariatric.

When the hours are itemized and tied to a specific CPT-code-defined service, the "cap" denial usually loses.

Post-concussion / mTBI: the ER assessment is not the cognitive workup

A common UHC and Cigna denial reads: "Patient was evaluated in the emergency department for the head injury. Neurocognitive testing is not medically necessary." That denial conflates acute neurological triage with cognitive characterization. The ED Glasgow Coma Scale, neurologic exam, and CT scan are designed to rule out hemorrhage and structural injury — not to characterize the cognitive sequelae.

The successful post-concussion appeal:

• Cite the AAN sport concussion guideline (Giza Neurology 2013) — neurocognitive assessment is recommended for symptomatic concussion / persistent post-concussion symptoms.
• Cite the CDC Pediatric mTBI Guideline (Lumba-Brown JAMA Pediatrics 2018) — comprehensive neurocognitive assessment is appropriate for symptomatic pediatric mTBI.
• Cite the AAN Mild TBI Guideline (Carney 2019) where adult.
• Submit the persistent symptom inventory (PCSS, RPQ, or equivalent) showing symptoms beyond the typical 7-14 day window.
• Submit prior provider notes documenting cognitive complaints not resolving on conservative management.
• Specify the battery's domains covered (executive, processing speed, attention, memory) and the role of return-to-work / return-to-school / return-to-play decision-making.

The CPT code is 96132 / 96133, not the ED E&M. They are not the same service.

Dementia / MCI workup: the imaging is not the diagnosis

Cigna and Humana Medicare Advantage at times deny dementia neuropsych workup because "MRI brain has been completed" or "screening (MMSE) is documented." Both arguments fail under the AAN MCI guideline.

The successful dementia / MCI appeal:

• Cite Petersen AAN MCI 2018 (Neurology) — neuropsych testing differentiates MCI from normal aging, MCI from major depression with cognitive features, and amnestic MCI from non-amnestic.
• Submit screening result (MoCA, MMSE, SLUMS) showing it was inconclusive or borderline.
• Submit MRI brain report (cite atrophy pattern, vascular burden, focal lesions). The MRI is the structural workup; the neuropsych battery is the cognitive workup. They answer different questions.
• Submit reversible-cause workup: TSH, B12, RPR (where indicated), CMP, HbA1c, depression screening (PHQ-9, GDS).
• Specify the differential the testing will resolve: MCI vs major depression vs early Alzheimer's vs frontotemporal vs Lewy body vs vascular cognitive impairment vs primary progressive aphasia.
• Cite NAN 2019 — referral question must change management. Treatment selection (cholinesterase inhibitor, memantine, antidepressant, anxiolytic), driving safety, capacity determination, advance care planning, and family counseling all depend on the cognitive profile.

ASD evaluation: ADOS-2 and ADI-R are gold standard

Anthem and several BCBS plans occasionally label ASD evaluation as "experimental" or "educational rather than medical." This is incorrect under DSM-5-TR.

The successful ASD evaluation appeal:

• Cite ADOS-2 (Autism Diagnostic Observation Schedule, 2nd edition, Lord et al.) and ADI-R (Autism Diagnostic Interview-Revised) — both are referenced as gold-standard diagnostic instruments in DSM-5-TR.
• Submit referral letter from pediatrician, developmental pediatrician, or psychiatrist with specific differential (e.g., "rule out ASD vs social anxiety vs language disorder vs specific learning disorder").
• Submit prior screening (SCQ, M-CHAT-R for young children, SRS-2) showing positive results.
• Document functional impairment across home, school, and social domains. Frame in terms of medical management (medication for comorbid anxiety / ADHD / aggression), not solely educational placement.
• Cite Wolraich AAP 2019 for pediatric ADHD differential where comorbidity is at stake.
• Cite NAN 2019 — the referral question (autism diagnosis) requires a standardized comprehensive battery beyond clinical interview.

Presurgical evaluations: the surgical team referral is critical

Three presurgical contexts come up most often: epilepsy surgery, deep brain stimulation, and bariatric surgery. Each has a controlling framework and a surgical-team protocol.

Epilepsy presurgical:

• Cite the ILAE (International League Against Epilepsy) presurgical framework and the AAN/AES intractable epilepsy practice parameter (Engel Neurology 2003 and subsequent updates).
• Submit referral letter from the epilepsy surgery team explicitly requesting neuropsych battery.
• Battery informs lateralization, language and memory dominance (often paired with Wada and / or fMRI), and post-operative cognitive prognosis.
• Wada is a separate procedure (95957 / 95958-family CPT codes) and is not duplicative of the cognitive battery.

DBS presurgical:

• Cite the Movement Disorder Society Task Force criteria and the CAPSIT-PD framework (Defer et al.) for Parkinson's disease.
• Submit referral letter from the DBS team.
• Battery rules out dementia (a relative contraindication to DBS), characterizes baseline cognitive status, and informs post-operative monitoring.

Bariatric presurgical:

• Cite the ASMBS / AACE / TOS 2019 clinical practice guidelines — preoperative psychological / psychiatric evaluation is a recommended component of bariatric surgical workup.
• Most major bariatric programs require it as a center protocol.
• Battery characterizes eating-disorder pathology, depression / anxiety, executive functioning relevant to dietary adherence, and capacity for informed consent.

Performance and symptom validity testing: build it into the battery and the appeal

Heilbronner et al. (NAN consensus, Clinical Neuropsychologist 2009) established that performance validity tests (PVTs — TOMM, MSVT, Word Memory Test, Reliable Digit Span, embedded indices) and symptom validity tests (SVTs — MMPI-3 / PAI validity scales) should be embedded in every neuropsychological battery. Insurers occasionally try to deny the time spent on validity testing as "non-essential." It is not. It is professional standard.

When the battery includes embedded PVTs, the appeal letter should say so explicitly and cite Heilbronner 2009 by name. Inclusion of validity testing also strengthens any appeal on the question of why a screening tool was insufficient — screens have no validity-testing component, and forensic / disability / capacity evaluations require it.

The peer-to-peer call: ask for a same-specialty reviewer

Almost every neuropsych denial carries a peer-to-peer review option, usually with a 14-day window. Demand it explicitly and demand a same-specialty reviewer. The insurer must provide a licensed psychologist or neuropsychologist — not a psychiatrist, not a family medicine physician, not an internist. That is a significant lever.

Bring three things to the call:

1. The referral question, framed in terms of NAN 2019 medical-necessity criteria.

2. The screening results showing they were inadequate.

3. The specific guideline citation (AAN MCI 2018, AAP ADHD 2019, AAN concussion 2013, ILAE / MDS / ASMBS for presurgical, DSM-5-TR for ASD).

A successful peer-to-peer often overturns the denial without a formal written appeal.

Letter structure that actually works

A neuropsych appeal letter should be 1.5 to 2 pages — long enough to address the denial point-by-point, short enough that the medical director will read it. Structure:

1. Header with member ID, claim #, service requested, CPT code (96132 / 96133 / 96136 / 96137 / 96130 / 96131 / 96116 as applicable).

2. Referral question + diagnosis + ICD-10 (1 paragraph, specific to the differential at stake).

3. Prior workup already obtained — screening tools + scores, imaging, labs, prior provider notes — and why each is insufficient.

4. Battery composition + qualifications — instruments planned by domain, embedded PVTs/SVTs per Heilbronner 2009, board-certification status.

5. Address the denial reason directly — quote the insurer's own coverage criteria, demonstrate each is met, cite NAN 2019 + the appropriate AAN / AAP / CDC / ILAE / ASMBS guideline + DSM-5-TR.

6. Closing — request overturn within deadline, demand peer-to-peer with a same-specialty reviewer.

Tone is professional, firm, evidence-driven. Avoid emotional language. The medical director responds to citations and policy mirroring, not to adjectives.

When to escalate

If the first-level appeal fails, the next step depends on plan type:

• Self-funded ERISA plans — second-level internal appeal, then external review (binding under ACA §2719).
• Fully-insured plans — state-mandated external review through the state insurance department.
• Medicare Advantage — Independent Review Entity (IRE) review, then ALJ hearing.
• Medicaid — state Fair Hearing.

Each level carries its own deadline (usually 60 to 180 days). Practices should track all of them and escalate efficiently. Most denials reverse on first appeal when the NAN 2019 framework is invoked correctly and the chart already contains the right screening data, imaging, and referral question.

What good looks like

A successful neuropsych appeal letter:

• Quotes the insurer's own policy by name and number (Aetna CPB 0158, UHC psychological/neuropsychological testing policy, Cigna coverage policy, Anthem CG-BEH-09).
• Cites NAN 2019 Medical Necessity Position Paper + AACN Practice Guidelines + the relevant AAN / AAP / CDC / ILAE / ASMBS guideline + DSM-5-TR by name.
• Includes screening scores (MoCA, MMSE, ASRS, CAARS T-scores), imaging report findings, lab values, and the planned battery composition by domain.
• Documents that brief screening was tried and was inadequate to answer the referral question.
• Itemizes hours by CPT code (96132 / 96133 / 96136 / 96137).
• Demands peer-to-peer with a same-specialty neuropsychologist or psychologist.
• Stays within 2 pages.

Most denials reverse on first appeal when these elements are present. The work is in the documentation — once the chart contains the right screening, imaging, labs, and referral question, drafting the letter is mechanical.